IPO activity accelerated across major markets, led by potentially record-sized U.S. offerings. Anthropic is preparing a public filing, while SB Energy targets at least $5 billion and General Atlantic revived listing plans. In Europe, Quantexa is weighing a London or U.S. IPO. Asia-Pacific activity includes a $1 billion Singapore data-center REIT and several Hong Kong technology listings. In Africa, Dangote Refinery advanced plans for a potential $5 billion Nigerian IPO after securing a $1 billion underwriting programme from its advisers.

German financial magazine FOCUS MONEY examines Oura’s planned IPO as the wearable technology company builds on strong growth and an expanding digital health platform. IPOX® Associate Lukas Muehlbauer comments on Oura’s positioning ahead of a potential listing, noting its evolution from a young wearable company into an established platform. He also highlights Oura’s focused product strategy versus larger technology groups, as the company targets further growth in the expanding global wearables market and recurring subscription-based customer revenue opportunities.

IPOX­® CEO Josef Schuster commented on Lyntris’ New York debut after shares fell 11.4%, valuing the defense contractor at $1.78 billion. Schuster said the market was discounting the company’s capital structure rather than treating it like a venture capital deal. He also noted that higher U.S. bond yields were pushing investors away from riskier, less-seasoned companies, including recent IPOs, even as earnings remained strong. Lyntris priced its IPO below its marketed range and reduced the offering size to 17 million shares, raising $297.5 million.

Global IPO activity is building across data centers, AI, semiconductors, robotics and consumer businesses. In the U.S., Vantage Data Centers is exploring a potential $10 billion IPO, while DayOne has confidentially filed for a $5 billion offering and Anthropic is meeting investors. Across Asia-Pacific, Moore Threads targets a major Hong Kong listing, alongside Vitalink, Mech-Mind and Kiwimoore. Malaysia’s ZUS Coffee and Japan’s Oliver are also advancing IPO plans, highlighting broader momentum across regional equity markets in 2026.

Reuters reports that Londian Wason’s NYSE debut valued the Chinese copper foil maker at about $2.01 billion, marking the largest U.S. IPO by a Chinese company in more than a year. IPOX® Research Associate Lukas Muehlbauer cautioned that the strong first-day performance, supported by a very low float and potential scarcity premium, should not be viewed as proof of a broader reopening for larger Chinese IPOs. He also highlighted potential future supply risks and customer concentration concerns for longer-term investors.

Global IPO activity is building across major markets, led by large planned offerings from Dangote Refinery, Moonshot AI, Nscale and Airtel Money. U.S. listings include Robinhood Ventures Fund II and Londian Wason, while Europe may see major transactions from KNDS and Kazakhstan’s KTZ. Hong Kong remains active with Moonshot AI and Sichuan Biokin, while Qatar’s Dandy advances its offering. Overall, the pipeline highlights strong investor interest in AI, infrastructure, financial services, industrials, biotechnology and energy-related issuers worldwide.

IPOX® Associate Muehlbauer was quoted in Reuters on Londian Wason’s planned U.S. IPO, which targets a valuation of up to $1.7 billion and could become the largest New York listing by a Chinese company in more than a year. He said the relatively small offering would be encouraging rather than signal a definitive market reopening, while highlighting stronger growth, profitability, battery demand, and investor concerns over the company’s reliance on a limited number of major customers for future growth prospects.

Global IPO activity spans major U.S., European and Asia-Pacific deals, led by potential multibillion-dollar listings from CyrusOne, Westinghouse and Nscale. Recent U.S. debuts from Jersey Mike’s and Reformation showed cautious investor sentiment, increasing pressure on pricing and fundraising expectations. Smaller transactions include Braveheart Bio, Space-Eyes, Karman Line, Vogenx and NASN Intelligent Tech. Across sectors, investors remain interested in established brands, nuclear energy, data centers, biotechnology, defense technology and artificial-intelligence infrastructure, despite heightened volatility and greater scrutiny of financial performance metrics.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Westinghouse Electric’s confidential U.S. IPO filing. He said the company’s investor appeal comes from offering exposure to nuclear growth through an established operating business and a well-known American industrial name. Muehlbauer added that energy-security concerns and rising electricity demand from data centers have improved market sentiment toward nuclear power.

IPOX® CEO Josef Schuster was featured in Bloomberg's ECM Watch, discussing muted U.S. IPO debuts and rising equity risk. Following mixed first-day performances from Jersey Mike’s and Reformation, Schuster said elevated risk is pressuring the IPO market and making investors more selective. He added that prospective issuers may need greater flexibility on pricing expectations and fundraising targets. Bloomberg also cited the IPOX® 100 U.S. as a benchmark for recent large U.S. IPOs and spinoffs amid volatile market conditions.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Jersey Mike’s NYSE debut, noting that raising roughly $1 billion showed investors remain willing to back large, established consumer brands. The sandwich chain’s shares opened 8.7% below their $23 IPO price, valuing the company at about $6.7 billion. Muehlbauer also cautioned against overinterpreting the first-day decline, citing broader market volatility as U.S. IPO activity continues to recover across technology, defense, industrial, consumer, and retail sectors this year after a prolonged slowdown.

Reuters reported that Permira-backed womenswear retailer Reformation was valued at $886.1 million in its NYSE debut after shares opened at the $15 IPO price. IPOX® Vice President Kat Liu said investors now prioritize financial performance over sustainability narratives, though sustainability can still strengthen brands and customer loyalty. Liu also noted that Reformation’s high share of returning customers signals genuine loyalty, lower retention costs, stronger lifetime spending, and more predictable revenue as the company pursues store expansion and product diversification plans.

Jersey Mike’s leads the pipeline with a potential $1.09 billion NYSE offering, followed by Reformation, Amapá Minerals and Saudi lubricant producer Petrolube. Other notable candidates include Lyntris, AlphaSense, Moonshot AI, AgiBot, TAWAL and Pepkor’s planned fintech spin-off. Together, the transactions span North America, Asia-Pacific, MENA and Africa, reflecting continued demand for sizable public-market opportunities across diverse industries and global markets.

Reuters reports that Permira-backed womenswear retailer Reformation is targeting a valuation of up to $1 billion in its U.S. IPO. IPOX® Vice President Kat Liu said consumer companies can still attract investors, but few retail brands offer enough recognition and differentiation. She noted Reformation’s sustainability positioning must compete with price, fashion trends and convenience. Liu added that its direct-to-consumer model improves control over pricing, merchandising, customer relationships and inventory, but is not a unique competitive advantage in today’s apparel market landscape.

Global IPO activity is accelerating, led by large technology and infrastructure deals. In the U.S., Switch, Anthropic, Holtec, JERA and YPF Electric Energy are pursuing or considering listings. Europe remains mixed, with Utmost and Howden advancing plans while AS Watson may delay. Asia-Pacific is especially active: CXMT has raised $8.6 billion, while Zhongji Innolight, Eoptolink, Shein, AirTrunk, DeepSeek and Kopi Kenangan prepare offerings, though Syngenta’s Hong Kong IPO could slip to 2027. Market conditions and regulatory approvals remain key uncertainties.